TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Septerna, Inc. ( (SEPN) ) is now available.
On September 25, 2025, Septerna, Inc. expanded its Board of Directors by appointing Keith Gottesdiener, M.D., a veteran biotechnology leader, as a Class I director and Chair of the newly formed R&D Committee. Dr. Gottesdiener’s extensive experience in advancing therapeutics and regulatory strategy is expected to significantly contribute to Septerna’s growth as it continues to develop its GPCR-targeted therapies and expand its clinical pipeline.
The most recent analyst rating on (SEPN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Septerna, Inc. stock, see the SEPN Stock Forecast page.
Spark’s Take on SEPN Stock
According to Spark, TipRanks’ AI Analyst, SEPN is a Neutral.
Septerna, Inc. shows strong technical momentum and positive corporate developments, but faces challenges with financial performance and valuation. The stock’s bullish trend and strategic partnerships are significant strengths, while operational inefficiencies and a high-risk valuation are key risks.
To see Spark’s full report on SEPN stock, click here.
More about Septerna, Inc.
Septerna, Inc. is a clinical-stage biotechnology company focused on advancing GPCR therapies using its proprietary Native Complex Platform. The company is developing a diverse pipeline of novel oral small molecule drug candidates targeting areas such as endocrinology, immunology, inflammation, and metabolic diseases.
Average Trading Volume: 247,820
Technical Sentiment Signal: Strong Buy
Current Market Cap: $778M
See more insights into SEPN stock on TipRanks’ Stock Analysis page.